Table 3.

Primary outcome measures

Process outcomes	Metformin	Placebo	Overall
Recruitment (of n=302 eligible population)			175/302 (57.9%)
Randomisation (of n=175 recruited)			144/175 (82.3%)
Attrition, n (%)*	35/67 (52.2%)	30/72 (46.8%)	65/139 (46.8%)
Women with adherence information, n (%)	56/71 (78.9%)	53/73 (72.6%)	109/144 (75.7%)
Adherence† 75%, n (%)‡	29/56 (51.8%)	30/53 (56.6%)	59/109 (54.1%)

Attrition is defined as loss to follow up or withdrawal from study; Adherence mean is calculated by averaging the adherence over the three visits using completed values. Women with adherence information on at least one visit are included in the calculations; Adherence rate.

*Women who became pregnant after randomisation are excluded from the denominator.

†Denominator included only women with adherence information.

‡75%=calculated the proportion of patients for whom we have adherence information on at least one visit and average adherence ≥75%.